TP53 wild-type

Our findings indicate that CXCL14 serves as a promising independent prognostic factor associated with an anti-tumor immune microenvironment in BRCA, with ECs identified as a major source. Furthermore, TP53 mutations may promote BRCA progression by repressing endothelial through CXCL14 transcription.

Nicotine's impact on p53 is highly context-dependent: it inactivates wild-type p53 while enhancing gain-of-function of mutant p53, particularly p53-RS. This review expands the theoretical framework of nicotine-induced carcinogenesis, highlights concerns regarding alternative nicotine delivery systems and crosstalk between oxidative stress and p53 regulation, and provides a scientific basis for early diagnosis, targeted therapy, and prevention of smoking-related cancers.

In real-world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first-line therapy in patients with TP53 wild-type CLL.

TP53 mutant erythroid and immature leukemia cells form spatial clusters segregated from T-cells in complete remission. An erythroblast-centered immunosuppressive niche characterizes TP53 mutant leukemia cells.

The complete response to levonorgestrel intra-uterine device therapy was lower than expected for endometrial intra-epithelial neoplasia. Response rates varied by molecular classification, with worse outcomes observed in deficient mismatch repair and p53 abnormal sub-types. Although limited by sample size, these findings suggest that levonorgestrel intra-uterine device therapy may not be sufficient for all molecular sub-groups.

HLS shows neither the classic morphology of LS nor dVIN but can be p53 aberrant/mutant. Because of its CK17/D2-40 immunophenotype, it should be considered as atypical LS.

Integrated cytogenetic and molecular profiling strongly predicted outcomes, while age, treatment intensity, and TP53 status emerged as dominant prognostic factors. These findings highlight the critical value of comprehensive genomic assessment to guide stratified AML management within the Irish population.

P3, N=257, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting

Vulvar aberrant maturation (VAM) encompasses HPVi lesions of uncertain neoplastic potential arising in lichen sclerosus that raise concern for but are not diagnostic of HPVi VIN. Collaboration between clinicians and pathologists is essential to achieve accurate diagnosis, optimal individualized treatment, and consistent application of this terminology in practice and research.

Our findings support the existence of 2 distinct molecular subgroups of CCOC, p53 normal and p53 abnormal, with diverse characteristics and patient outcomes. Clinical and molecular differences were discovered within these subgroups.

We discuss the recent literature describing the added diagnostic value of immunohistochemical biomarkers p53, CK17, CK13, SOX2, GATA3, GLUT1 and others, which may be particularly helpful when morphology is inconclusive. It is anticipated that with improved VSCC classification and precursor recognition, avenues for more tailored therapeutic strategies and earlier therapeutic intervention can be achieved.

In this study, we created a p53-knockout cell line to determine if residual p53 has any gain-of-function growth-promoting activities. Our results demonstrate that cells without p53 grow slower, indicating that residual p53 has tumor-promoting functions and a conformation like that of mutant p53 when in complex with E6, indicating alternative mechanisms by which HPV can subvert the function of p53.